Filtered By:
Drug: Celebrex
Management: Food and Drug Administration (FDA)

This page shows you your search results in order of date.

Order by Relevance | Date

Total 2 results found since Jan 2013.

Drug Safety: Fasinumab Evaluated in Clinical Trials, Plus Celecoxib May Not Pose Increased Heart Attack or Stroke Risk
After an independent review, ongoing clinical trials investigating the safety of fasinumab for treating hip or knee OA will discontinue the use of higher fasinumab doses...
Source: The Rheumatologist - May 15, 2018 Category: Rheumatology Authors: Michele B. Kaufman, PharmD, BCGP Tags: Drug Updates Safety celecoxib Drug Safety fasinumab FDA hip knee Knee Osteoarthritis (OA) Nonsteroidal anti-inflammatory drugs (NSAIDs) Pain Pain Management U.S. Food and Drug Administration (FDA) Source Type: research

Experts Urge Sparing Use of Nonaspirin Painkillers
The Food and Drug Administration said it would ask drug manufacturers to change the labels to reflect evidence that nonaspirin, nonsteroidal anti-inflammatory drugs increased the risk of heart attacks and strokes.
Source: NYT Health - July 14, 2015 Category: Consumer Health News Authors: SABRINA TAVERNISE Tags: Pain-Relieving Drugs Heart Aleve (Drug) Celebrex (Drug) Drugs (Pharmaceuticals) Motrin IB Food and Drug Administration Labeling and Labels (Product) Stroke Ibuprofen (Drug) Source Type: news